VT-1021 is under clinical development by Vigeo Therapeutics and currently in Phase III for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase III drugs for Recurrent Glioblastoma Multiforme (GBM) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how VT-1021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VT-1021 overview
VT-1021 is under development for the treatment of solid tumors including epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic ductal adenocarcinoma, triple-negative breast cancer and glioblastoma. The drug candidate comprises of D-psaptide and cyclopsaptide, derived from naturally-occurring human protein, prosaposin. It acts by targeting CD36 receptor and Leukocyte Surface Antigen CD47. It is administered through intravenous route.
Vigeo Therapeutics overview
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors. The company is headquartered in Boston, Massachusetts, the US
For a complete picture of VT-1021’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
